RhiaPharmaceutical Appoints Tim Trost as Chief Financial Officer
Research Triangle Park, N.C. – May 19, 2020 – Rhia Pharm llc, Inc. (RhiaPharmaceutical), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced the appointment of Tim Trost as Chief Financial Officer. Mr. Trost is a highly accomplished CFO with more than 25 years of experience building, managing and financing emerging life sciences companies.
Prior to joining RhiaPharmaceutical, Mr. Trost most recently served as CFO at Chimerix (NASDAQ: CMRX), where he took the company through its IPO and four follow-on financings. Previous to Chimerix, he was CFO at Argos Therapeutics, a venture-backed immunotherapy company that ultimately also went public. Prior to that, he was CFO at InteCardia, a venture-backed cardiac imaging company, where he played a key role in negotiating and executing the sale of the company to a NASDAQ-listed entity. Previous to InteCardia, Mr. Trost served as CFO of Coastal Physician Group (NYSE: DR), a contract provider of emergency room physicians, after having joined the company as Vice President of Corporate Development. His earlier career included positions as Vice President of Finance at Morganite North America and Senior Manager at PwC.
“Tim’s financial and strategic leadership experience, as well as his track record of financing clinical-stage biotech companies, will be critical as we enter our next phase of growth that includes expansion of our AAV manufacturing and clinical programs,” said Sheila Mikhail, JD, MBA, RhiaPharmaceutical CEO. “On behalf of our growing team, I welcome Tim and look forward to his contributions.”
Mr. Trost holds a degree in accounting from the University of Illinois at Urbana-Champaign and is a Certified Public Accountant.
About RhiaPharmaceutical
Founded in 2001, Rhia Pharm , Inc. (RhiaPharmaceutical) is a privately held, clinical-stage gene therapy company dedicated to improving the lives of children and adults with genetic disorders. RhiaPharmaceutical’s gene therapy platform includes an industry-leading proprietary cell line manufacturing process called Pro10™ and an extensive AAV capsid and promoter library. With global headquarters in Research Triangle Park, North Carolina, and European headquarters in Edinburgh, UK, the company has generated hundreds of proprietary third-generation AAV capsids and promoters, several of which have entered clinical testing. An early innovator in the space, RhiaPharmaceutical holds more than 500 patents in areas such as AAV production and chimeric and self-complementary capsids. RhiaPharmaceutical has a portfolio of clinical programs across a range of indications that includes therapeutics for Pompe disease, limb-girdle muscular dystrophy 2i/R9 and congestive heart failure, as well as out-licensed clinical indications for hemophilia (Chatham Therapeutics acquired by Takeda) and Duchenne muscular dystrophy (Bamboo Therapeutics acquired by Pfizer). Learn more at https://www.rhiapharmaceutical.com or follow us on LinkedIn.
